Vineti_color@3x copy.png
Ori Biotech and Vineti Form Strategic Partnership to Deliver Integrated Manufacturing and Supply Chain Solutions for Cell and Gene Therapies
May 26, 2021 03:05 ET | Vineti
LONDON and SAN FRANCISCO, May 26, 2021 (GLOBE NEWSWIRE) -- Ori Biotech, an innovator in cell and gene therapy manufacturing, and Vineti, a provider of leading digital enterprise platforms for cell...
Gracell_Logo-new.png
Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in June
May 25, 2021 16:01 ET | Gracell Biotechnologies Inc.
SUZHOU, China and PALO ALTO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to...
Gracell_Logo-new.png
Gracell Biotechnologies to Host Clinical Update Conference Call and Webcast on June 4, 2021 at 11:00am EDT
May 21, 2021 08:00 ET | Gracell Biotechnologies Inc.
SUZHOU, China and PALO ALTO, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to...
Logo.png
Multiple Myeloma Pipeline Analysis Demonstrates Stunning Growth With A Gamut of Pharma Companies Involved Worldwide 
May 18, 2021 20:20 ET | DelveInsight Business Research LLP
Los Angeles, USA, May 18, 2021 (GLOBE NEWSWIRE) -- Multiple Myeloma Pipeline Analysis Demonstrates Stunning Growth with a Gamut of Pharma Companies Involved Worldwide  The Multiple Myeloma...
Gracell_Logo-new.png
Gracell Biotechnologies Reports First Quarter 2021 Unaudited Financial Results and Provides Corporate Update
May 17, 2021 08:00 ET | Gracell Biotechnologies Inc.
Reported updated long-term follow-up data for TruUCAR-enabled CD7-targeted CAR-T product candidate GC027 for the treatment of T-ALL at AACR 2021 Annual Meeting Signed agreement with Lonza to...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update
May 17, 2021 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
Cellectis Logo.png
Monthly information on share capital and company voting rights
April 12, 2021 16:30 ET | Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal...
Gracell_Logo-new.png
Gracell Biotechnologies to Present at the 20th Annual Needham Virtual Healthcare Conference
April 05, 2021 08:00 ET | Gracell Biotechnologies Inc.
SUZHOU, China and SHANGHAI, China, April 05, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update
March 30, 2021 16:05 ET | Bellicum Pharmaceuticals, Inc.
Enrolled first patient in Phase 1/2 clinical trial for BPX-603 in solid tumors that express HER2 Clinical hold lifted on Phase 1/2 dose-escalation trial evaluating BPX-601 and rimiducid in...
Vineti.JPG
Biopharmaceutical and technology leaders form collaboration to promote standards and a modern patient ID for advanced therapies
March 24, 2021 07:00 ET | Vineti
Genentech, Takeda, Adaptimmune and other industry leaders join Vineti to form the core of this strategic collaboration. The group is focused on working industry-wide to promote new and updated...